We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Mapping Reveals Genes that Contribute to Hypertension

By LabMedica International staff writers
Posted on 18 May 2009
Cardiovascular disease researchers used advanced gene mapping techniques to search for genes directly linked to blood pressure regulation.

High blood pressure (hypertension) is a syndrome that contributes to the risk of stroke, heart attack, and kidney failure, among other conditions. More...
Approximately 30% or more of adults suffer from high blood pressure, and experts suggest that it contributes to millions of deaths worldwide each year. While factors in the environment such as diet, physical activity, and stress affect blood pressure, there is also an important genetic influence that may contribute to the likelihood of an individual developing hypertension.

To study the genetic basis for high blood pressure investigators at Johns Hopkins University (Baltimore, MD, USA) mapped the genomes of nearly 30,000 people of European descent who were participants in the [U.S.] National Institutes of Health's ARIC (Atherosclerosis Risk in Communities) project. The subjects had average systolic blood pressures ranging from 118 mmHg to 143 mmHg and average diastolic blood pressures ranging from 72 mmHg to 83 mmHg.

Results published in the May 10, 2009, online edition of the journal Nature Genetics revealed that high blood pressure was linked to a mutation in the ATP2B1 gene, which codes for a calcium pump protein. A mutation in the SH2B3 gene, which codes for a protein involved in the immune response, was also found in individuals with increased blood pressure. In some of these individuals there were also mutations in genes involved in cell growth as well as genes necessary for correct heart development.

"Strikingly, none of the genes we identified as having common variation are part of the system we know about that regulates blood pressure – the genes identified are not the ones targeted by current prescription drugs to control hypertension,” said contributing author Dr. Aravinda Chakravarti, professor of genetic medicine at Johns Hopkins University. "If we can increase the number of genes implicated in blood pressure maintenance from the current 12 to the expected 50 in the next year, our understanding of the biology will change completely.”

"Hypertension is difficult to study; it is a trait, not a disease per se unless left untreated, and many things contribute to it,” said Dr. Chakravarti. "These findings identify more pathways important for blood pressure maintenance and may lead to improvements in hypertension therapy and the formation of early detection systems.”

Related Links:
Johns Hopkins University



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.